Results 151 to 160 of about 27,171 (223)

Recommendations for acceleration of vaccine development and emergency use filings for COVID-19 leveraging lessons from the novel oral polio vaccine. [PDF]

NPJ Vaccines, 2021
Thiel N, Selwyn C, Murphy G, Simpson S, Chakrabarti AC.   +4 more
europepmc   +1 more source

Novel Oral Polio Vaccine Type 2 Use for Polio Outbreak Response: A Global Effort for a Global Health Emergency. [PDF]

Pathogens
Kurji FD, Bandyopadhyay AS, Zipursky S, Cooper LV, Gast C, Toher M, Clemens R, Clemens SAC, Prasad R, Azhari A.   +9 more
europepmc   +1 more source

Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial. [PDF]

Vaccine, 2021
Zaman K, Kovacs SD, Vanderende K, Aziz A, Yunus M, Khan S, Snider CJ, An Q, Estivariz CF, Oberste MS, Pallansch MA, Anand A.   +11 more
europepmc   +1 more source

Impact of Supplementary Immunization Activities using Novel Oral Polio Vaccine Type 2 during a Large outbreak of Circulating Vaccine-Derived Poliovirus in Nigeria. [PDF]

J Infect Dis
Voorman A, Lyons H, Shuaib F, Adamu US, Korir C, Erbeto T, Bandyopadhyay AS, Okiror S.   +7 more
europepmc   +1 more source

Analysis of vaccination campaign effectiveness and population immunity to support and sustain polio elimination in Nigeria [PDF]

, 2016

core   +1 more source

Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes [PDF]

, 2015

core   +1 more source

Time for a Worldwide Shift from Oral Polio Vaccine to Inactivated Polio Vaccine [PDF]

Clinical Infectious Diseases, 2009
openaire   +3 more sources

Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study. [PDF]

Lancet Infect Dis
Bashorun AO, Kotei L, Jawla O, Jallow AF, Saidy AJ, Kinteh MA, Kujabi A, Jobarteh T, Kanu FJ, Donkor SA, Ezeani E, Fofana S, Njie M, Ceesay L, Jafri B, Williams A, Jeffries D, Kotanmi B, Mainou BA, Ooko M, Clarke E.   +20 more
europepmc   +1 more source

Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience.

Vaccine, 2023
Macklin GR, Peak C, Eisenhawer M, Kurji F, Mach O, Konz J, Gast C, Bachtiar NS, Bandyopadhyay AS, Zipursky S, nOPV2 Working Group.   +10 more
europepmc   +1 more source